
The drug Tepezza has already been celebrated by the pharmaceutical industry as the first FDA-approved drug for the treatment of thyroid eye disease, also known as Graves' ophthalmopathy. The company behind the drug, Horizon Therapeutics, is now eager to better understand the long-term use of the drug.
This is why Horizon is beginning a new clinical trial of the drug, which was originally developed by Danish biotech company Genmab, to study the effects of the drug on the chronic version of the disease.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app